Q3 2024 · 13F-HR
BAKER BROS. ADVISORS LPholdings as filed
Filed 2024-11-14 · accession 0001104659-24-118899
$9.65B
Reported value
93
Positions
2024-09-30
Period end
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 07725L102 | ONC | BeiGene, Ltd. | $2.37B | 24.6% | 10,568,897 | Common | SOLE |
| 45337C102 | INCY | Incyte Corporation | $2.03B | 21.1% | 30,739,020 | Common | SOLE |
| 004225108 | ACAD | ACADIA Pharmaceuticals Inc. | $659.5M | 6.83% | 42,877,916 | Common | SOLE |
| 86627T108 | SMMT | Summit Therapeutics Inc. | $534.9M | 5.54% | 24,424,865 | Common | SOLE |
| 558868105 | MDGL | Madrigal Pharmaceuticals, Inc. | $419.0M | 4.34% | 1,974,590 | Common | SOLE |
| 76155X100 | RVMD | Revolution Medicines, Inc. | $343.3M | 3.56% | 7,569,090 | Common | SOLE |
| 76243J105 | RYTM | Rhythm Pharmaceuticals, Inc. | $335.2M | 3.47% | 6,398,366 | Common | SOLE |
| 457669307 | INSM | Insmed Incorporated | $322.4M | 3.34% | 4,415,918 | Common | SOLE |
| 501575104 | KYMR | Kymera Therapeutics, Inc. | $283.8M | 2.94% | 5,995,929 | Common | SOLE |
| 088786108 | BCYC | Bicycle Therapeutics plc | $212.7M | 2.20% | 9,399,960 | Common | SOLE |
| 28036F105 | EWTX | Edgewise Therapeutics, Inc. | $155.9M | 1.62% | 5,840,059 | Common | SOLE |
| 76029N106 | REPL | Replimune Group, Inc. | $121.1M | 1.25% | 11,045,336 | Common | SOLE |
| G01767105 | ALKS | Alkermes plc | $117.0M | 1.21% | 4,181,751 | Common | SOLE |
| 24823R105 | DNLI | Denali Therapeutics Inc. | $108.7M | 1.13% | 3,731,695 | Common | SOLE |
| 457669AB5 | INSM 0.75 06/01/28 | Insmed Incorporated | $98.3M | 1.02% | 42,850,000 | Common | SOLE |
| 90400D108 | RARE | Ultragenyx Pharmaceutical Inc. | $87.6M | 0.91% | 1,576,114 | Common | SOLE |
| 67080M103 | NRIX | Nurix Therapeutics, Inc. | $87.2M | 0.90% | 3,882,125 | Common | SOLE |
| 29384C108 | TRDA | Entrada Therapeutics, Inc. | $77.8M | 0.81% | 4,865,819 | Common | SOLE |
| N44445109 | IMTX | Immatics N.V. | $73.5M | 0.76% | 6,443,398 | Common | SOLE |
| 00288U106 | ABCL | AbCellera Biologics Inc. | $71.6M | 0.74% | 27,525,640 | Common | SOLE |
| G52694109 | KNSA | Kiniksa Pharmaceuticals International, plc | $70.4M | 0.73% | 2,818,323 | Common | SOLE |
| 449585108 | 1K0 | IGM Biosciences, Inc. | $67.7M | 0.70% | 4,092,310 | Common | SOLE |
| 04016X101 | ARGX | argenx SE | $60.7M | 0.63% | 111,904 | Common | SOLE |
| 86150R107 | STOK | Stoke Therapeutics, Inc. | $53.7M | 0.56% | 4,368,443 | Common | SOLE |
| 45258D105 | IMCR | Immunocore Holdings plc | $47.2M | 0.49% | 1,515,318 | Common | SOLE |
| 50015M109 | KOD | Kodiak Sciences Inc. | $45.2M | 0.47% | 17,310,490 | Common | SOLE |
| 81749D107 | SERA | Sera Prognostics, Inc. | $42.4M | 0.44% | 5,434,399 | Common | SOLE |
| H17182108 | CRSP | CRISPR Therapeutics AG | $39.6M | 0.41% | 843,075 | Common | SOLE |
| 98420N105 | XENE | Xenon Pharmaceuticals Inc. | $39.1M | 0.41% | 993,679 | Common | SOLE |
| 45258J102 | IMVT | Immunovant, Inc. | $34.9M | 0.36% | 1,225,410 | Common | SOLE |
| 157085101 | CERS | Cerus Corporation | $33.9M | 0.35% | 19,477,339 | Common | SOLE |
| 45166A102 | IDYA | IDEAYA Biosciences, Inc. | $33.6M | 0.35% | 1,062,123 | Common | SOLE |
| G76279101 | ROIV | Roivant Sciences Ltd. | $32.3M | 0.33% | 2,798,716 | Common | SOLE |
| 00973Y108 | AKRO | Akero Therapeutics, Inc. | $31.5M | 0.33% | 1,097,082 | Common | SOLE |
| 501147102 | KRYS | Krystal Biotech, Inc. | $30.9M | 0.32% | 169,934 | Common | SOLE |
| 15102K100 | CELC | Celcuity Inc. | $28.0M | 0.29% | 1,874,978 | Common | SOLE |
| 61225M102 | GLUE | Monte Rosa Therapeutics, Inc. | $26.1M | 0.27% | 4,916,095 | Common | SOLE |
| 26818M108 | DYN | Dyne Therapeutics, Inc. | $24.1M | 0.25% | 672,096 | Common | SOLE |
| 09077A106 | BMEA | Biomea Fusion, Inc. | $21.3M | 0.22% | 2,108,949 | Common | SOLE |
| 055477103 | BCAX | Bicara Therapeutics Inc. | $21.2M | 0.22% | 833,333 | Common | SOLE |
| 74065P101 | PRLD | Prelude Therapeutics Inc. | $21.0M | 0.22% | 10,123,824 | Common | SOLE |
| 152309100 | CNTA | Centessa Pharmaceuticals plc | $19.6M | 0.20% | 1,227,178 | Common | SOLE |
| 64135M105 | NGNE | Neurogene Inc. | $19.1M | 0.20% | 456,015 | Common | SOLE |
| 74006W207 | PRAX | Praxis Precision Medicines, Inc. | $18.6M | 0.19% | 323,105 | Common | SOLE |
| 022307102 | ALMS | Alumis Inc. | $16.7M | 0.17% | 1,562,500 | Common | SOLE |
| N5749R100 | 2GH | Merus N.V. | $15.0M | 0.16% | 300,000 | Common | SOLE |
| 89854M101 | TCRX | TScan Therapeutics, Inc. | $13.9M | 0.14% | 2,784,792 | Common | SOLE |
| 640979100 | NMRA | Neumora Therapeutics, Inc. | $13.7M | 0.14% | 1,034,600 | Common | SOLE |
| 98401F105 | XNCR | Xencor, Inc. | $13.5M | 0.14% | 670,431 | Common | SOLE |
| 901384107 | TSVT* | 2seventy bio, Inc. | $11.8M | 0.12% | 2,497,526 | Common | SOLE |
| 31189P102 | FATE | Fate Therapeutics, Inc. | $10.5M | 0.11% | 2,997,772 | Common | SOLE |
| 04335A105 | ARVN | Arvinas, Inc. | $10.0M | 0.10% | 405,576 | Common | SOLE |
| 799566104 | SANA | Sana Biotechnology, Inc. | $9.9M | 0.10% | 2,380,949 | Common | SOLE |
| 25056L103 | DSGN | Design Therapeutics, Inc. | $9.4M | 0.10% | 1,743,725 | Common | SOLE |
| 462222100 | IONS | Ionis Pharmaceuticals, Inc. | $9.0M | 0.09% | 223,470 | Common | SOLE |
| 68386J208 | OPTEY | Opthea Limited | $8.8M | 0.09% | 2,173,622 | Common | SOLE |
| 15117B202 | CLDX | Celldex Therapeutics, Inc. | $8.4M | 0.09% | 247,644 | Common | SOLE |
| 75943R102 | RLAY | Relay Therapeutics, Inc. | $8.2M | 0.09% | 1,160,117 | Common | SOLE |
| 92539P101 | — | Verve Therapeutics, Inc. | $8.2M | 0.08% | 1,691,530 | Common | SOLE |
| 877619106 | TSHA | Taysha Gene Therapies, Inc. | $8.0M | 0.08% | 4,004,756 | Common | SOLE |
| 604749101 | MIRM | Mirum Pharmaceuticals, Inc. | $7.4M | 0.08% | 190,476 | Common | SOLE |
| 21217B100 | CTNM | Contineum Therapeutics, Inc. | $6.0M | 0.06% | 312,500 | Common | SOLE |
| 87583X109 | TNGX | Tango Therapeutics, Inc. | $5.8M | 0.06% | 750,000 | Common | SOLE |
| 83086J200 | SKYE | Skye Bioscience, Inc. | $5.6M | 0.06% | 1,434,634 | Common | SOLE |
| 92243G108 | PCVX | Vaxcyte, Inc. | $5.6M | 0.06% | 48,885 | Common | SOLE |
| 22663K107 | CRNX | Crinetics Pharmaceuticals, Inc. | $5.3M | 0.06% | 103,927 | Common | SOLE |
| 23306J200 | — | DBV Technologies S.A. | $5.1M | 0.05% | 7,307,131 | Common | SOLE |
| 483119202 | KALAEUR | KALA BIO, Inc. | $5.1M | 0.05% | 891,335 | Common | SOLE |
| 37148K100 | GBIOGBX | Generation Bio Co. | $4.8M | 0.05% | 1,944,945 | Common | SOLE |
| 014442107 | ALEC | Alector, Inc. | $4.3M | 0.04% | 927,264 | Common | SOLE |
| 74168J101 | PRME | Prime Medicine, Inc. | $4.0M | 0.04% | 1,028,466 | Common | SOLE |
| 786700104 | SGMT | Sagimet Biosciences Inc. | $3.8M | 0.04% | 1,381,898 | Common | SOLE |
| 86366E106 | GPCR | Structure Therapeutics Inc. | $3.8M | 0.04% | 85,500 | Common | SOLE |
| 03969T109 | ARCT | Arcturus Therapeutics Holdings Inc. | $3.5M | 0.04% | 151,329 | Common | SOLE |
| 43906K209 | HOOK | HOOKIPA Pharma Inc. | $3.5M | 0.04% | 812,814 | Common | SOLE |
| 52187K200 | CYPH | Leap Therapeutics, Inc. | $3.0M | 0.03% | 1,172,175 | Common | SOLE |
| 29337E102 | ELVN | Enliven Therapeutics, Inc. | $2.9M | 0.03% | 114,833 | Common | SOLE |
| 20454B104 | CMPX | Compass Therapeutics, Inc. | $2.9M | 0.03% | 1,557,630 | Common | SOLE |
| Y95308105 | WVE | Wave Life Sciences Ltd. | $2.8M | 0.03% | 344,063 | Common | SOLE |
| 59045L106 | — | Mersana Therapeutics, Inc. | $2.1M | 0.02% | 1,086,115 | Common | SOLE |
| N62509109 | NAMS | NewAmsterdam Pharma Company N.V. | $1.6M | 0.02% | 96,711 | Common | SOLE |
| 15673T100 | IPSC | Century Therapeutics, Inc. | $1.4M | 0.01% | 797,460 | Common | SOLE |
| 918385204 | VTVT | vTv Therapeutics, Inc. | $1.3M | 0.01% | 97,314 | Common | SOLE |
| 008064107 | — | Aerovate Therapeutics, Inc. | $1.3M | 0.01% | 628,939 | Common | SOLE |
| 717081103 | PFE | Pfizer Inc. | $1.0M | 0.01% | 35,000 | Common | SOLE |
| 74365U107 | TARA | Protara Therapeutics, Inc. | $982,403 | 0.01% | 536,832 | Common | SOLE |
| 01626L204 | ALGS | Aligos Therapeutics, Inc. | $719,256 | 0.01% | 83,055 | Common | SOLE |
| 09058V103 | BCRX | BioCryst Pharmaceuticals, Inc. | $575,913 | 0.01% | 75,778 | Common | SOLE |
| 69353Y103 | PMVP | PMV Pharmaceuticals, Inc. | $479,816 | 0.00% | 322,024 | Common | SOLE |
| 344174107 | FHTX | Foghorn Therapeutics Inc. | $419,201 | 0.00% | 45,027 | Common | SOLE |
| 004890109 | ACRV | Acrivon Therapeutics, Inc. | $370,195 | 0.00% | 52,885 | Common | SOLE |
| 90240B106 | TYRA | Tyra Biosciences, Inc. | $249,371 | 0.00% | 10,607 | Common | SOLE |
| 86889P117 | SRZNW | Surrozen, Inc. | $8,583 | 0.00% | 833,333 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.